Neoadjuvant Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

The Choice of Treatment Methods and Efficacy of LABC
Conditions: Locally Advanced Breast Cancer Interventions: Procedure: Modified radical mastectomy for breast cancer; Procedure: neoadjuvant therapy; Procedure: Systematic treatment Sponsors: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: PHESGO Sponsors: Latin American Cooperative Oncology Group; Roche Pharma AG; Oncocl ínicas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
Conditions: Prostate Cancer Interventions: Drug: 177Lu rhPSMA-10.1; Drug: Degarelix Sponsors: M.D. Anderson Cancer Center; AVEO Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials

" neoBREASTIM " : Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Conditions: Triple Negative Breast Neoplasms Interventions: Combination Product: Atezolizumab + RP1 Sponsors: Institut Curie; Replimune Inc.; Roche Pharma AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer; Neoadjuvant Therapy; Radiotherapy; Immunotherapy Interventions: Drug: Toripalimab; Radiation: Conventional segmental radiotherapy; Other: opreation Sponsors: Northern Jiangsu Province People ' s Hospital; Shanghai Junshi Bioscience Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials

Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy
Conditions: Esophageal Cancer Interventions: Other: follow up Sponsors: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
Conditions:   Bladder Cancer;   Adult Solid Tumor Interventions:   Drug: Nivolumab;   Drug: Visugromab (CTL-002);   Drug: Placebo Sponsor:   CatalYm GmbH Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
Conditions: Bladder Cancer; Adult Solid Tumor Interventions: Drug: Nivolumab; Drug: Visugromab (CTL-002); Drug: Placebo Sponsors: CatalYm GmbH Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: capecitabine;   Drug: tislelizumab;   Drug: thymalfasin;   Radiation: long-term radiotherapy Sponsors:   Beijing Friendship Hospital;   Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Condition:   Locally Advanced Cervical Cancer Interventions:   Drug: Zimberelimab;   Drug: Albumin-bound Paclitaxel;   Drug: Cisplatin Sponsor:   Tang-Du Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Conditions: Locally Advanced Cervical Cancer Interventions: Drug: Zimberelimab; Drug: Albumin-bound Paclitaxel; Drug: Cisplatin Sponsors: Tang-Du Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Conditions: Locally Advanced Rectal Cancer Interventions: Drug: capecitabine; Drug: tislelizumab; Drug: thymalfasin; Radiation: long-term radiotherapy Sponsors: Beijing Friendship Hospital; Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy Interventions: Drug: Tislelizumab Sponsors: Guo Xufeng Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Condition:   Lung Cancer Interventions:   Drug: Sacituzumab Govitecan;   Drug: Pembrolizumab Sponsor:   Chinese University of Hong Kong Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
Condition:   Gastric Cancer Intervention:   Drug: sintilimab+metronomic PLOF Sponsor:   Huashan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials